newsfilter
← Latest News
GlobeNewswire·

Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront and